A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients
Allocation: Randomized Stratified
Key Inclusion Criteria:
Key Exclusion Criteria:
Chapel Hill, North Carolina 27599-7584, United States
Ciudad de Buenos Aires, Buenos Aires C1121ABE, Argentina
Ciudad de Buenos Aires, Buenos Aires C1181ACH, Argentina
Prov. Buenos Aires, Buenos Aires 1629, Argentina
Prov de Santa Fe, Santa Fe Province 2000, Argentina
Westmead Nsw, New South Wales 2145, Australia
Greenslopes Qld, Queensland 4120, Australia
Cisanello (pisa), 56124, Italy